HYFT
ImmunoPrecise Antibodies Ltd.
1.30$
+0.4%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.1% | 0.0% | 46.0% | 55.0% | 51.5% | 103.9% | 35.6% | 43.3% | 44.0% | 50.8% | 44.7% | 41.2% | |
| -0.1% | 0.0% | 54.0% | 45.0% | 48.5% | -3.9% | 64.4% | 56.7% | 56.0% | 49.2% | 55.3% | 58.8% | |
| 35.2% | 16.0% | 25.1% | 9.4% | 4.4% | 3.2% | 11.0% | 39.6% | 68.2% | 16.5% | 20.2% | 31.7% | |
| 3.7% | 52.6% | 70.6% | 104.1% | 67.1% | 54.0% | 70.2% | 79.4% | 74.4% | 63.6% | 60.1% | 125.0% | |
| 3.7% | 87.2% | 106.7% | 135.6% | 105.4% | 25.2% | 87.7% | 142.8% | 179.9% | 105.3% | 105.0% | 154.8% | |
| -3.7% | 12.8% | -52.7% | -90.6% | -57.0% | -29.1% | -23.3% | -86.1% | -123.9% | -56.1% | -49.7% | -96.0% | |
| 0.0% | 0.0% | 0.6% | 1.5% | 7.9% | 5.0% | 3.4% | 0.4% | 0.1% | 0.1% | 0.0% | 0.0% | |
| -3.5% | 12.8% | -207.8% | -93.0% | -69.7% | -37.7% | -33.5% | -81.8% | -134.3% | -117.1% | -139.8% | -100.0% | |
| 0.0% | 4.8% | -3.1% | 2.0% | 0.0% | -2.5% | 7.5% | 4.4% | -5.8% | -10.6% | -16.4% | -2.9% | |
| -3.5% | 8.0% | -204.7% | -95.0% | -69.7% | -35.2% | -41.0% | -86.3% | -128.5% | -106.5% | -123.3% | -89.7% | |
| -3.5% | 15.5% | -205.3% | -79.9% | -36.9% | -8.4% | -7.9% | -61.9% | -101.8% | -93.6% | -117.7% | -85.7% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.